AI Mammography Scores Signal Paradigm Shift Toward Proactive, Tech-Enabled Breast Cancer Prevention

The Swedish retrospective analysis of 31,394 women and 88,963 mammograms, published in Radiology, demonstrates that three commercial AI-CAD tools flagged elevated risk scores up to six years before radiologist detection in roughly 20% of eventual cancers. This observational cohort study from the VAI-B database lacks randomization or prospective validation, limiting causal inference, yet its large sample and multi-vendor testing strengthen external applicability. No conflicts of interest were declared by the Karolinska team. Beyond the reported 90% specificity thresholds, the work reveals a missed opportunity: integrating longitudinal AI trajectories with polygenic risk scores could enable truly personalized intervals, a strategy already piloted in the UK-based PROCAS2 observational cohort of over 50,000 women. A 2024 Nature Medicine study further showed that AI-augmented risk models reduced interval cancers by 23% when used to triage supplemental MRI, underscoring the under-covered trend of tech-enabled prevention over reactive screening. Critics rightly note that retrospective designs inflate performance; ongoing RCTs such as the AI-STREAM trial will clarify real-world impact. Collectively these findings reposition AI not as a replacement reader but as an early-alert system that could compress the preclinical window, provided health systems address equity gaps in diverse populations.